Additionally, an integrative analysis of tumors demonstrated that, in comparison to primary colorectal cancer (pCRC), peritoneal metastasis (PM) features a comparable KRAS mutation rate, but with an increased incidence of GNAS (mucinous) and BRAF (non-mucinous) pathways. This evidence concerns the gene KRAS and colorectal cancer.